235 research outputs found
Diabetic renal disease
Diabetic nephropathy (DN) is an important long-term complication
of diabetes. DN is now the most common cause
of end-stage renal disease (ESRD) in many countries [1].
Both the increasing prevalence of type 2 DMand increased
acceptance of diabetic patients into renal replacement therapy
(RRT) programmes have contributed to this. Indeed,
there has been a marked increase in the incidence of renal
replacement therapy (RRT) for type 2 DM over time [1]. DN
is also a major burden on health care budgets [2] and is
associated with a reduction in health-related quality of life [3,
4].Moreover, DN is associated with increased cardiovascular
mortality in both type 1 and type 2 diabetic patients [5, 6].peer-reviewe
Impact of recycled aggregate brick on the physical-mechanical and environmental characteristics of cement treated bases
Recycled aggregate brick (RAB) constitutes a significant waste stream in developed countries, originating from brick manufacturing and demolition processes. This paper investigates the potential utilization of various sizes of RAB as replacements for natural aggregate (NA) in cement-treated bases (CTB), along with an assessment of their mechanical and environmental properties. The study includes a life cycle analysis to evaluate the environmental impacts of different CTB formulations. The novelty of this study lies in the environmental evaluation of four types of CTB, including natural, recycled, and mixed CTB. The physical and mechanical properties of the recycled brick and natural materials are characterized and compared. Results indicate that recycled brick aggregates, when combined with a cement mixture, can be used as a base and sub-base layer with good mechanical performance. Moreover, environmental analyses demonstrate that recycled aggregate generates fewer impacts than natural aggregates. Consequently, this study suggests that the utilization of recycled aggregates brick in CTB offers a sustainable waste management solution while simultaneously contributing to the reduction of environmental impacts associated with construction activities
La variation de lâĂ©quilibre glycĂ©mique (mais pas du poids) est corrĂ©lĂ©e positivement Ă la modification du risque cardiovasculaire absolu chez le patient diabĂ©tique
Lower-extremity amputation as a marker for renal and cardiovascular events and mortality in patients with long standing type 1 diabetes
International audienceAbstractBackgroundWe evaluated the risks of renal and cardiovascular complications, and mortality associated with lower extremity amputation (LEA) in patients with type 1 diabetes.MethodsWe studied two cohorts of people with long standing type 1 diabetes: GENEDIAB (n = 456) and GENESIS (n = 611). Subsets of the cohorts (n = 260, n = 544) were followed for 9 and 5 years, respectively. Outcomes were the incidence of end stage renal disease (ESRD), myocardial infarction, stroke and mortality during follow-up. Analyses were performed in pooled cohorts.ResultsThe prevalence of LEA at baseline was 9.3 % (n = 99). A positive history of LEA was associated with the baseline prevalence of established (OR 4.50, 95 % CI 2.33â8.91, p < 0.0001) and advanced diabetic nephropathy (OR 5.50, 95 % CI 2.89â10.78, p < 0.0001), ESRD (OR 2.86, 95 % CI 1.43â5.50, p = 0.004), myocardial infarction (OR 3.25, 95 % CI 1.68â6.15, p = 0.0006) and stroke (OR 3.88, 95 % CI 1.67â8.72, p = 0.002, adjusted for sex, age, and cohort membership). A positive history of LEA at baseline was associated with the incidence during follow-up of ESRD (HR 2.69, 95 % CI 1.17â6.20, p = 0.02), and myocardial infarction (HR 3.53, 95 % CI 1.79â6.97, p = 0.0001). History of LEA was also associated with increased risk for all-cause (HR 3.55, 95 % CI 2.05â6.16, p < 0.0001), cardiovascular (HR 3.30, 95 % CI 1.36â8.02, p = 0.008), infectious disease (HR 5.18, 95 % CI 1.13â23.84, p = 0.03) and other-cause mortality (HR 2.81, 95 % CI 1.09â7.26, p = 0.03). History of LEA at baseline was associated with a 40 % reduction in the duration of survival in the subset of patients who died during follow-up. Population attributable risk of the history of LEA at baseline for total mortality during follow-up was 0.31.ConclusionsPatients with LEA have a higher risk of ESRD, myocardial infarction and cardiovascular and non-cardiovascular mortality. Our results highlight the importance of LEA as a key-predictor for major vascular events and premature death in type 1 diabetic patients
Allele Dependent DNA Methylation of the Human Insulin Gene Promoter in T2D patients and Controls
International audienc
Associations of microvascular complications with all-cause death in patients with diabetes and COVID-19:the CORONADO, ABCD Covid-19 audit and AMERICADO study groups
AIM: To provide a detailled analysis of the microvascular burden in patients with diabetes hopitalized for COVDâ19. MATERIALS AND METHODS: We analysed data from the French CORONADO initiative and the UK Association of British Clinical Diabetologists (ABCD) COVIDâ19 audit, two nationwide multicentre studies, and the AMERICADO, a multicentre study conducted in New York area. We assessed the association between risk of allâcause death during hospital stay and the following microvascular complications in patients with diabetes hospitalized for COVIDâ19: diabetic retinopathy and/or diabetic kidney disease and/or history of diabetic foot ulcer. RESULTS: Among 2951 CORONADO, 3387 ABCD COVIDâ19 audit and 9327 AMERICADO participants, microvascular diabetic complications status was ascertained for 1314 (44.5%), 1809 (53.4%) and 7367 (79.0%) patients, respectively: 1010, 1059 and 1800, respectively, had â„1 severe microvascular complication(s) and 304, 750 and 5567, respectively, were free of any complications. The patients with isolated diabetic kidney disease had an increased risk of allâcause death during hospital stay: odds ratio [OR] 2.53 (95% confidence interval [CI] 1.66â3.83), OR 1.24 (95% CI 1.00â1.56) and OR 1.66 (95% CI 1.40â1.95) in the CORONADO, the ABCD COVIDâ19 national audit and the AMERICADO studies, respectively. After adjustment for age, sex, hypertension and cardiovascular disease (CVD), compared to those without microvascular complications, patients with microvascular complications had an increased risk of allâcause death during hospital stay in the CORONADO, the ABCD COVIDâ19 diabetes national audit and the AMERICADO studies: adjusted OR ((adj)OR) 2.57 (95% CI 1.69â3.92), (adj)OR 1.22 (95% CI 1.00â1.52) and (adj)OR 1.33 (95% CI 1.15â1.53), respectively. In metaâanalysis of the three studies, compared to patients free of complications, those with microvascular complications had an unadjusted OR for allâcause death during hospital stay of 2.05 (95% CI 1.42â2.97), which decreased to 1.62 (95% CI 1.19â2.119) after adjustment for age and sex, and to 1.50 (1.12â2.02) after hypertension and CVD were further added to the model. CONCLUSION: Microvascular burden is associated with an increased risk of death in patients hospitalized for COVIDâ19
Genome-wide association study on coronary artery disease in type 1 diabetes suggests beta-defensin 127 as a risk locus
Aims Diabetes is a known risk factor for coronary artery disease (CAD). There is accumulating evidence that CAD pathogenesis differs for individuals with type 1 diabetes (T1D). However, the genetic background has not been extensively studied. We aimed to discover genetic loci increasing CAD susceptibility, especially in T1D, to examine the function of these discoveries and to study the role of the known risk loci in T1D. Methods and results We performed the largest genome-wide association study to date for CAD in T1D, comprising 4869 individuals with T1D (cases/controls: 941/3928). Two loci reached genome-wide significance, rs1970112 in CDKN2B-AS1 [odds ratio (OR) =1.32, P = 1.50 x 10(-8)], and rs6055069 on DEFB127 promoter (OR= 4.17, P= 2.35 x 10(-9)), with consistent results in survival analysis. The CDKN2B-AS1 variant replicated (P = 0.04) when adjusted for diabetic kidney disease in three additional T1D cohorts (cases/controls: 434/3123). Furthermore, we explored the function of the lead discoveries with a cardio-phenome-wide analysis. Among the eight suggestive loci (P <1 x 10(-6)), rs70962766 near B3GNT2 associated with central blood pressure, rs1344228 near CNTNAP5 with intima media thickness, and rs2112481 on GRAMD2B promoter with serum leucocyte concentration. Finally, we calculated genetic risk scores for individuals with T1D with the known susceptibility loci. General population risk variants were modestly but significantly associated with CAD also in T1D (P=4.21 x 10(-7)). Conclusion While general population CAD risk loci had limited effect on the risk in T1D, for the first time, variants at the CDKN2B-AS1 locus were robustly associated with CAD in individuals with T1D. The novel finding on beta-defensin DEFB127 promoter provides a link between diabetes, infection susceptibility, and CAD, although pending on future confirmation. [GRAPHICS] .Peer reviewe
Atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes: review of recent evidence-based guidelines
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality and morbidity in individuals with type 2 diabetes mellitus (T2DM). Accordingly, several scientific societies have released clinical practice guidelines to assist health professionals in ASCVD risk management in patients with T2DM. However, some recommendations differ from each other, contributing to uncertainty about the optimal clinical management of patients with T2DM and established ASCVD or at high risk for ASCVD. Thus, the purpose of this paper is to discuss recent evidence-based guidelines on ASCVD risk stratification and prevention in patients with T2DM, in terms of disparities and similarities. To close the gap between different guidelines, a multidisciplinary approach involving general practitioners, endocrinologists, and cardiologists may enhance the coordination of diagnosis, therapy, and long-term follow-up of ASCVD in patients with T2DM
The T-381C SNP in BNP gene may be modestly associated with type 2 diabetes: an updated meta-analysis in 49 279 subjects
A recent study reported an association between the brain natriuretic peptide (BNP) promoter T-381C polymorphism (rs198389) and protection against type 2 diabetes (T2D). As replication in several studies is mandatory to confirm genetic results, we analyzed the T-381C polymorphism in seven independent case-control cohorts and in 291 T2D-enriched pedigrees totalling 39 557 subjects of European origin. A meta-analysis of the seven case-control studies (n = 39 040) showed a nominal protective effect [odds ratio (OR) = 0.86 (0.79-0.94), P = 0.0006] of the CC genotype on T2D risk, consistent with the previous study. By combining all available data (n = 49 279), we further confirmed a modest contribution of the BNP T-381C polymorphism for protection against T2D [OR = 0.86 (0.80-0.92), P = 1.4 Ă 10â5]. Potential confounders such as gender, age, obesity status or family history were tested in 4335 T2D and 4179 normoglycemic subjects and they had no influence on T2D risk. This study provides further evidence of a modest contribution of the BNP T-381C polymorphism in protection against T2D and illustrates the difficulty of unambiguously proving modest-sized associations even with large sample size
- âŠ